SCHEMBL23709904

SCHEMBL23709904

COC(=O)/C(=C/c1ccc(Cl)cc1Oc1cc(Cl)ccc1Cl)N=[N+]=[N-]

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RHEB Q15382 3/20 0.35
▸ GPBAR1 Q8TDU6 2/20 0.32
▸ TTR P02766 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ MAPT P10636 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ POLB P06746 1/20 0.31
▸ PLA2G1B P04054 1/20 0.31
▸ ATG4B Q9Y4P1 1/20 0.31
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535973 0.89 HTR2A (0.41) CYP3A4CYP2D6CYP2C19SCN9A
SCHEMBL20535972 0.89 HTR2A (0.41) CYP3A4CYP2D6CYP2C19SCN9A
SCHEMBL30009048 0.88 MAPT (0.38) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL24113456 0.88 MAPT (0.38) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL20535305 0.87 RHEB (0.40) RHEBGPBAR1TTRMEN1KMT2A
SCHEMBL20535306 0.87 RHEB (0.40) RHEBGPBAR1TTRMEN1KMT2A
SCHEMBL20536123 0.87 L3MBTL1 (0.39) MEN1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL20536125 0.87 L3MBTL1 (0.39) MEN1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL23709945 0.86 LMNA (0.41) RHEBMEN1KMT2ACYP1A2CYP3A4
SCHEMBL18990257 0.86 POLB (0.34) MEN1KMT2AMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS RHEB 1/4885GPBAR1 966/4885TTR 4120/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS RHEB 1/4885GPBAR1 781/4885TTR 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback